A study from Yale University today in JAMA Network Open reveals substantial protection by the preventive drug nirsevimab ...

High uptake of RSVpreF vaccine and nirsevimab was observed, with 64% of pregnant individuals and 70% of infants receiving them. Factors such as older maternal age, private insurance, and receipt ...

Estimated effectiveness was 65% against hospitalization, 74% against pediatric intensive care unit admission, and 64% against ...

Nearly three fourths of infants born during the 2023-2024 respiratory syncytial virus (RSV) season received protection with either nirsevimab or exposure to maternal RSVpreF, with maternal RSVpreF ...

Getting vaccinated during pregnancy protects your newborn from severe infection during the first critical months of life.

From next Monday, 17 March, free immunisation from respiratory syncytial virus (RSV) will be available to all newborn babies.

From next Monday, 17 March, free immunisation from respiratory syncytial virus (RSV) will be available to all newborn babies.It will mean all newborn ...

Nirsevimab is a long-acting monoclonal antibody designed to provide passive immunity against RSV in infants and young children. The Advisory Committee on Immunization Practices (ACIP) recommends ...

Sanofi joins force with Samitivej International Children’s Hospital to launch the “Together Against RSV” awareness campaign in Thailand, with the support from the Pediatric Infectious Disease Society ...

The Vermont pandemic death total stands at 1,278 as of March 6, 2025, an increase of 2 from the previous week (the most ...

The medication – nirsevimab – is given via injection to infants under 8 months old. Unlike a vaccine, the immunization provides a ready-made supply of antibody protection to babies without ...